FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3075615690> ?p ?o ?g. }

• W3075615690 endingPage "08014" @default.
• W3075615690 startingPage "08014" @default.
• W3075615690 abstract "Under the auspices of the Protein Analysis Working Group (PAWG) of the Comité Consultatif pour la Quantité de Matière (CCQM) a key comparison, CCQM-K115.b, was coordinated by the Bureau International des Poids et Mesures (BIPM) and the Chinese National Institute of Metrology (NIM). Seven Metrology Institutes or Designated Institutes and the BIPM participated. Participants were required to assign the mass fraction of oxytocin (OXT) present as the main component in the comparison sample for CCQM-K115.b. The comparison samples were prepared from synthetic OXT purchased from a commercial supplier and used as provided without further treatment or purification. OXT was selected to be representative of the performance of a laboratory's measurement capability for the purity assignment of chemically synthesized peptides of known sequence, with one cross-link and up to 5 kDa. It was anticipated to provide an analytical measurement challenge representative for the value-assignment of compounds of broadly similar structural characteristics. The majority of participants used amino acid analysis (PICAA) or quantitative nuclear magnetic resonance (PICqNMR) spectroscopy with a correction for structurally-related peptide impurities approach as the amount of material that has been provided to each participant (25 mg) is insufficient to perform a full mass balance based characterization of the material by a participating laboratory. The coordinators, both the BIPM and the NIM, were the laboratories to use the mass balance approach as they had more material available. It was decided to propose KCRVs for both the OXT mass fraction and the mass fraction of the peptide related impurities as indispensable contributor regardless of the use of PICAA, PICqNMR or mass balance to determine the OXT purity. This allowed participants to demonstrate the efficacy of their implementation of the approaches used to determine the OXT mass fraction. In particular, it allows participants to demonstrate the efficacy of their implementation of peptide related impurity identification and quantification. More detailed studies on the identification/quantification of peptide related impurities and the hydrolysis efficiency revealed that the integrity of the impurity profile of the related peptide impurities obtained by the participant is crucial for the impact on accuracy of the OXT mass fraction assignment. The assessment of the mass fraction of peptide impurities is based on the assumption that only the Largest Consistent Subset (LCS) of results is taken for the calculation of the KCRV PepImp by use of the weighted mean. The KCRV PepImp of 31.6 mg/g is associated with a small corresponding expanded uncertainty of ±1.4 mg/g (k =2) providing a more realistic basis of evaluation for the capabilities of the participants to identify/quantify peptide related impurities. Inspection of the degree of equivalence plots for the mass fraction of peptide impurities and additional information obtained from the peptide related impurity profile indicates that in many cases the major related peptide impurities have been identified and quantified. The approach selected to obtain a KCRV OXT for the mass fraction of OXT is based on random-effects meta-analysis (DerSimonian-Laird (DSL) variance-weighted mean). The DSLmean takes into account the uncertainties of the results while introducing sufficient excess variance to allow for their observed dispersion resulting in a larger expanded uncertainty U(KCRV OXT ). The KCRV OXT for CCQM-K115.b is 787.2 mg/g with a corresponding expanded uncertainty of the KCRV OXT of ±12.9 mg/g. All OXT mass fraction results except the result of NMIM are in agreement with the KCRV OXT . It should be pointed out that the mass balance approaches show smaller uncertainties than PICAA or PICqNMR approaches. Mass balance approaches seem to produce slightly higher OXT mass fractions while PICAA approaches deliver slightly lower OXT mass fractions. Main text To reach the main text of this paper, click on Final Report . Note that this text is that which appears in Appendix B of the BIPM key comparison database kcdb.bipm.org/ . The final report has been peer-reviewed and approved for publication by the CCQM, according to the provisions of the CIPM Mutual Recognition Arrangement (CIPM MRA)." @default.
• W3075615690 created "2020-08-24" @default.
• W3075615690 creator A5000083701 @default.
• W3075615690 creator A5000563267 @default.
• W3075615690 creator A5005751849 @default.
• W3075615690 creator A5007614806 @default.
• W3075615690 creator A5012296211 @default.
• W3075615690 creator A5023715229 @default.
• W3075615690 creator A5025177524 @default.
• W3075615690 creator A5026147542 @default.
• W3075615690 creator A5032456042 @default.
• W3075615690 creator A5049761666 @default.
• W3075615690 creator A5050121818 @default.
• W3075615690 creator A5050932380 @default.
• W3075615690 creator A5052061698 @default.
• W3075615690 creator A5053328711 @default.
• W3075615690 creator A5060745278 @default.
• W3075615690 creator A5063578382 @default.
• W3075615690 creator A5063583470 @default.
• W3075615690 creator A5068729100 @default.
• W3075615690 creator A5068936754 @default.
• W3075615690 creator A5069633631 @default.
• W3075615690 creator A5070883766 @default.
• W3075615690 creator A5071882334 @default.
• W3075615690 creator A5077105471 @default.
• W3075615690 creator A5078798628 @default.
• W3075615690 creator A5079738744 @default.
• W3075615690 creator A5081164592 @default.
• W3075615690 creator A5081232691 @default.
• W3075615690 creator A5082880089 @default.
• W3075615690 creator A5083839129 @default.
• W3075615690 creator A5086931394 @default.
• W3075615690 date "2020-01-01" @default.
• W3075615690 modified "2023-09-27" @default.
• W3075615690 title "Key comparison study on peptide purity - synthetic oxytocin" @default.
• W3075615690 doi "https://doi.org/10.1088/0026-1394/57/1a/08014" @default.
• W3075615690 hasPublicationYear "2020" @default.
• W3075615690 type Work @default.
• W3075615690 sameAs 3075615690 @default.
• W3075615690 citedByCount "5" @default.
• W3075615690 countsByYear W30756156902021 @default.
• W3075615690 countsByYear W30756156902022 @default.
• W3075615690 crossrefType "journal-article" @default.
• W3075615690 hasAuthorship W3075615690A5000083701 @default.
• W3075615690 hasAuthorship W3075615690A5000563267 @default.
• W3075615690 hasAuthorship W3075615690A5005751849 @default.
• W3075615690 hasAuthorship W3075615690A5007614806 @default.
• W3075615690 hasAuthorship W3075615690A5012296211 @default.
• W3075615690 hasAuthorship W3075615690A5023715229 @default.
• W3075615690 hasAuthorship W3075615690A5025177524 @default.
• W3075615690 hasAuthorship W3075615690A5026147542 @default.
• W3075615690 hasAuthorship W3075615690A5032456042 @default.
• W3075615690 hasAuthorship W3075615690A5049761666 @default.
• W3075615690 hasAuthorship W3075615690A5050121818 @default.
• W3075615690 hasAuthorship W3075615690A5050932380 @default.
• W3075615690 hasAuthorship W3075615690A5052061698 @default.
• W3075615690 hasAuthorship W3075615690A5053328711 @default.
• W3075615690 hasAuthorship W3075615690A5060745278 @default.
• W3075615690 hasAuthorship W3075615690A5063578382 @default.
• W3075615690 hasAuthorship W3075615690A5063583470 @default.
• W3075615690 hasAuthorship W3075615690A5068729100 @default.
• W3075615690 hasAuthorship W3075615690A5068936754 @default.
• W3075615690 hasAuthorship W3075615690A5069633631 @default.
• W3075615690 hasAuthorship W3075615690A5070883766 @default.
• W3075615690 hasAuthorship W3075615690A5071882334 @default.
• W3075615690 hasAuthorship W3075615690A5077105471 @default.
• W3075615690 hasAuthorship W3075615690A5078798628 @default.
• W3075615690 hasAuthorship W3075615690A5079738744 @default.
• W3075615690 hasAuthorship W3075615690A5081164592 @default.
• W3075615690 hasAuthorship W3075615690A5081232691 @default.
• W3075615690 hasAuthorship W3075615690A5082880089 @default.
• W3075615690 hasAuthorship W3075615690A5083839129 @default.
• W3075615690 hasAuthorship W3075615690A5086931394 @default.
• W3075615690 hasConcept C105795698 @default.
• W3075615690 hasConcept C113196181 @default.
• W3075615690 hasConcept C116628846 @default.
• W3075615690 hasConcept C144133560 @default.
• W3075615690 hasConcept C149629883 @default.
• W3075615690 hasConcept C155202549 @default.
• W3075615690 hasConcept C162356407 @default.
• W3075615690 hasConcept C171250308 @default.
• W3075615690 hasConcept C178790620 @default.
• W3075615690 hasConcept C185592680 @default.
• W3075615690 hasConcept C192562407 @default.
• W3075615690 hasConcept C195766429 @default.
• W3075615690 hasConcept C2780841128 @default.
• W3075615690 hasConcept C2993070364 @default.
• W3075615690 hasConcept C2993899435 @default.
• W3075615690 hasConcept C33923547 @default.
• W3075615690 hasConcept C41008148 @default.
• W3075615690 hasConcept C43617362 @default.
• W3075615690 hasConcept C515207424 @default.
• W3075615690 hasConcept C55493867 @default.
• W3075615690 hasConceptScore W3075615690C105795698 @default.
• W3075615690 hasConceptScore W3075615690C113196181 @default.
• W3075615690 hasConceptScore W3075615690C116628846 @default.
• W3075615690 hasConceptScore W3075615690C144133560 @default.
• W3075615690 hasConceptScore W3075615690C149629883 @default.

• next